Algert Global LLC Stoke Therapeutics, Inc. Transaction History

Algert Global LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $13,513 - $21,654	-4,010 Reduced 24.23%	12,540 $66,000
Q3 2023 Nov 13, 2023	SELL	$3.78 - $11.99 $69,166 - $219,393	-18,298 Reduced 52.51%	16,550 $65,000
Q1 2023 May 12, 2023	BUY	$7.65 - $10.38 $189,322 - $256,884	24,748 Added 245.03%	34,848 $290,000
Q4 2022 Feb 13, 2023	SELL	$7.07 - $15.69 $493,825 - $1.1 Million	-69,848 Reduced 87.37%	10,100 $93,000
Q3 2022 Nov 15, 2022	BUY	$12.56 - $22.53 $1 Million - $1.8 Million	79,948 New	79,948 $1.03 Million

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $434M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.